{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Urothelial+Cell+Cancer&page=2", "query": { "condition": "Metastatic Urothelial Cell Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Urothelial+Cell+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T20:17:39.762Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03115801", "title": "A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma", "Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Radiation & immunotherapy", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "19 Years to 90 Years" }, "enrollment_count": 6, "start_date": "2016-11", "completion_date": "2020-10-13", "has_results": true, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-07-23T20:17:39.762Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03115801" }, { "nct_id": "NCT04963153", "title": "Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Bladder Urothelial Carcinoma", "Recurrent Renal Pelvis Urothelial Carcinoma", "Recurrent Ureter Urothelial Carcinoma", "Recurrent Urethral Urothelial Carcinoma", "Recurrent Urothelial Carcinoma", "Stage IIIB Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-07-07", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-07-23T20:17:39.762Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04963153" }, { "nct_id": "NCT02807636", "title": "Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1213, "start_date": "2016-06-30", "completion_date": "2024-02-12", "has_results": true, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-07-23T20:17:39.762Z", "location_count": 18, "location_summary": "Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02807636" }, { "nct_id": "NCT04953104", "title": "ARID1A and/or KDM6A Mutation and CXCL13 Expression", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Bladder Urothelial Carcinoma", "Recurrent Renal Pelvis Urothelial Carcinoma", "Recurrent Ureter Urothelial Carcinoma", "Recurrent Urethral Urothelial Carcinoma", "Recurrent Urothelial Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Unresectable Bladder Urothelial Carcinoma", "Unresectable Renal Pelvis Urothelial Carcinoma", "Unresectable Ureter Urothelial Carcinoma", "Unresectable Urethral Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-09-21", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-07-23T20:17:39.762Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04953104" }, { "nct_id": "NCT05867121", "title": "A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RO7496353", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2023-10-02", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-07-23T20:17:39.762Z", "location_count": 3, "location_summary": "Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867121" }, { "nct_id": "NCT04306900", "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "TTX-030, budigalimab and mFOLFOX6", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030, budigalimab and docetaxel", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030 and mFOLFOX6", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030 and budigalimab", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030, budigalimab, nab-paclitaxel and gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030 and pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030, nab-paclitaxel and gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Budigalimab and mFOLFOX6", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Trishula Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "18 Years to 110 Years" }, "enrollment_count": 185, "start_date": "2020-03-30", "completion_date": "2024-03-27", "has_results": true, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-07-23T20:17:39.762Z", "location_count": 26, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04306900" }, { "nct_id": "NCT07532902", "title": "A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Pleural Mesothelioma", "Gastroesophageal Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Platinum", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-04-07", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-07-23T20:17:39.762Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07532902" }, { "nct_id": "NCT03590054", "title": "Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage III Cutaneous Melanoma", "Stage IV Cutaneous Melanoma", "Locally Advanced Melanoma", "Locally Advanced Solid Neoplasm", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Urothelial Carcinoma", "Non-Small Cell Lung Carcinoma", "Stage IB Lung Cancer AJCC v7", "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Abexinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2018-08-20", "completion_date": "2023-11-30", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-07-23T20:17:39.762Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03590054" }, { "nct_id": "NCT00005831", "title": "Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Squamous Cell Carcinoma of the Bladder", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-14", "last_synced_at": "2026-07-23T20:17:39.762Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005831" }, { "nct_id": "NCT04623502", "title": "An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Kidney Cancer", "Renal Cell Carcinoma", "Clear Cell Carcinoma", "Urothelial Carcinoma", "Metastatic Kidney Cancer", "Metastatic Urothelial Carcinoma", "Papillary Renal Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Fumarate Hydratase Deficiency", "Succinate Dehydrogenase-Deficient Renal Cell Carcinoma", "HLRCC", "Hereditary Leiomyomatosis and Renal Cell Cancer" ], "interventions": [ { "name": "13C-Glucose", "type": "OTHER" }, { "name": "13C-Acetate", "type": "OTHER" }, { "name": "13C-Lactate", "type": "OTHER" }, { "name": "13C-Glutamine", "type": "OTHER" }, { "name": "13C-Fructose", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2019-09-30", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-07-23T20:17:39.762Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04623502" } ] }